Tag: irinotecan
ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain...
A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the brain and treat patients with...
FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan
Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab...
Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan
In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies had signed an exclusive license...
Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...
Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...
Peptide-drug Conjugates: Potent and Selective Miniaturized Conjugates for the Treatment of...
Targeted therapeutics, including antibody-drug conjugates ADCs, designed to link targeted monoclonal antibodies, via a linker, to potent cell-killing payloads, have been a highly successful for creating...
United States Patent and Trademark Office Awards New Patents to Immunomedics
Earlier this month the United States Patent and Trademark Office awarded U.S. Patent 9,458,242 to Immunomedics for additional claims under the patent family “Dosages of...
Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results
Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
